Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.78 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.70 |
| ▸ | AURKA | O14965 | 2/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.66 |
| ▸ | EGFR | P00533 | 3/20 | 0.66 |
| ▸ | KDR | P35968 | 7/20 | 0.65 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15519356 | 0.88 | HDAC1 (1.00) | HDAC1AURKBAURKAMAPK14EGFR | |
| SCHEMBL15519874 | 0.88 | HDAC1 (0.72) | HDAC1AURKBAURKAMAPK14EGFR | |
| SCHEMBL8933899 | 0.84 | AURKB (0.94) | AURKBAURKAMAPK14EGFRKDR | |
| Hydrochloric Acid SCHEMBL8807597 | 0.83 | AURKB (0.92) | AURKBAURKAMAPK14EGFRKDR | |
| Anilinoquinazoline1 SCHEMBL30195580 | 0.83 | AURKB (1.00) | AURKBAURKAMAPK14EGFRKDR | |
| Anilinoquinazoline1 SCHEMBL1066538 | 0.83 | AURKB (1.00) | AURKBAURKAMAPK14EGFRKDR | |
| Anilinoquinazoline1 SCHEMBL3968007 | 0.82 | AURKB (0.98) | AURKBAURKAMAPK14EGFRKDR | |
| SCHEMBL15579863 | 0.81 | KDR (0.68) | HDAC1AURKBAURKAMAPK14EGFR | |
| Hydrochloric Acid SCHEMBL8814111 | 0.81 | EGFR (0.85) | AURKBAURKAEGFRKDRIRAK4 | |
| SCHEMBL15520080 | 0.80 | HDAC1 (0.71) | HDAC1AURKBAURKAMAPK14EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034886-B2 | 4-aminoquinazoline derivatives and uses thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-05-19 | — | — | US | claimed |
| US-20140235633-A1 | 4-Aminoquinazoline Derivatives and Uses Thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2014-08-21 | — | — | US | claimed |
| EP-2708532-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND USES THEREOF | Jiangsu Hengyi Pharmaceutical Co.,Ltd (CN) | 2014-03-19 | — | — | EP | claimed |
| US-9034886-B2 | 4-aminoquinazoline derivatives and uses thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-05-19 | — | — | US | disclosed |
| US-9034886-B2 | 4-aminoquinazoline derivatives and uses thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-05-19 | — | — | US | disclosed |
| US-9034886-B2 | 4-aminoquinazoline derivatives and uses thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-05-19 | — | — | US | disclosed |
| US-20140235633-A1 | 4-Aminoquinazoline Derivatives and Uses Thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2014-08-21 | — | — | US | disclosed |
| US-20140235633-A1 | 4-Aminoquinazoline Derivatives and Uses Thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2014-08-21 | — | — | US | disclosed |
| US-20140235633-A1 | 4-Aminoquinazoline Derivatives and Uses Thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2014-08-21 | — | — | US | disclosed |
| EP-2708532-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND USES THEREOF | Jiangsu Hengyi Pharmaceutical Co.,Ltd (CN) | 2014-03-19 | — | — | EP | disclosed |
| EP-2708532-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND USES THEREOF | Jiangsu Hengyi Pharmaceutical Co.,Ltd (CN) | 2014-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235633-A1 | 4-Aminoquinazoline Derivatives and Uses Thereof | HDAC5, HDAC4, HDAC1 | HDAC1 3/4885AURKB 347/4885AURKA 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.